Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy
European Respiratory Journal · 2025
DOI: 10.1183/13993003.01683-2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Alena Moiseenko und 24 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust, Wellcome Trust/Department of Health, Medicor Foundation.
Abstract (Originalsprache)
Rationale and objective Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CFTR modulators offer significant improvements, but ∼10% of patients remain nonresponsive or are intolerant. This study provides an analysis of rSIV.F/HN, a lentiviral vector optimised for lung delivery, including CFTR protein expression, functional correction of CFTR defects and genomic integration site analysis in preparation for a first-in-human clinical trial.
Methods
Air–liquid interface cultures of primary human bronchial epithelial cells (HBECs) from CF patients (F508del/F508del), as well as a CFTR-deficient immortalised human lung epithelial cell line mimicking class I (CFTR-null) homozygous mutations, were used to assess transduction efficiency. Quantification methods included a novel proximity ligation assay for CFTR protein expression. For assessment of CFTR channel activity, Ussing chamber studies were conducted. The safety profile was assessed using integration site analysis and in vitro insertional mutagenesis studies. Results rSIV.F/HN expressed CFTR and restored CFTR-mediated chloride currents to physiological levels in primary F508del/F508del HBECs as well as in a class I cells. In contrast, the latter could not be achieved by small-molecule CFTR modulators, underscoring the potential of gene therapy for this mutation class. Combination of rSIV.F/HN-CFTR with the potentiator ivacaftor showed a greater than additive effect. The genomic integration pattern showed no site predominance (frequency of occurrence ≤10%), and a low risk of insertional mutagenesis was observed in an in vitro immortalisation assay.
Conclusions
The results underscore rSIV.F/HN as a promising gene therapy vector for CF, providing a mutation-agnostic treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany.
- UK Respiratory Gene Therapy Consortium, London, UK.
- National Heart and Lung Institute, Imperial College London, London, UK.
- Centre of Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Depts of Respiratory Medicine and Paediatric Respiratory Medicine, Royal Brompton Hospital, Guy's and St Thomas' Trust, London, UK.
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Förderung
- Wellcome Trust
- Wellcome Trust/Department of Health
- Medicor Foundation
- Boehringer Ingelheim
Zitieren
APA
Moiseenko, A., Sinadinos, A., Sergijenko, A., Pineault, K., Saleh, A., Nekola, K., Strang, N., Eleftheraki, A., Boyd, A. C., Davies, J. C., Gill, D. R., Hyde, S. C., McLachlan, G., Rath, T., Rothe, M., Schambach, A., Hobbie, S., Schuler, M., Maier, U., …, & Kreuz, S. (2025). Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy. European Respiratory Journal. https://doi.org/10.1183/13993003.01683-2023
Vancouver
Moiseenko A, Sinadinos A, Sergijenko A, Pineault K, Saleh A, Nekola K, et al. Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy. European Respiratory Journal. 2025. doi:10.1183/13993003.01683-2023
BibTeX
@article{Moiseenko2025,
author = {Moiseenko, Alena and Sinadinos, Anthony and Sergijenko, Ana and Pineault, Kyriel and Saleh, Aarash and Nekola, Konradin and Strang, Nathalie and Eleftheraki, Anastasia and Boyd, A Christopher and Davies, Jane C and Gill, Deborah R and Hyde, Stephen C and McLachlan, Gerry and Rath, Tim and Rothe, Michael and Schambach, Axel and Hobbie, Silke and Schuler, Michael and Maier, Udo and Thomas, Matthew J and Mennerich, Detlev and Schmidt, Manfred and Griesenbach, Uta and Alton, Eric W F W and Kreuz, Sebastian},
title = {Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.01683-2023}
}
EUVIMED